Pfizer begins a Phase 1/2 study to evaluate respiratory syncytial virus (RSV) vaccine

Pfizer Inc. (NYSE:PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus t…
Read the full story: Breaking World Pharma News